GISP Supplement and Profiles, 2012
Figure A Data - Age of GISP Participants, 2012
Figure B Data - Race/Ethnicity of GISP Participants, 2012
Figure C Data - Percentage of GISP Participants Identifying as Men Who Have Sex with Men, 2000-2012
Figure D Data - Primary Antibiotic Used to Treat Gonorrhea among GISP Participants, 2012
Figure E Data - Secondary Antibiotic Used to Treat Gonorrhea among GISP Participants, 2012
Figure F Data - Resistance to Penicillin, Tetracycline, and Ciprofloxacin among GISP Isolates, 2012
Figure G Data – Distribution of Minimum Inhibitory Concentrations (MICs) of Ceftriaxone among GISP Isolates, 2008-2012
Figure H Data - Distribution of Minimum Inhibitory Concentrations (MICs) of Cefixime among GISP Isolates, 2009-2012
Figure I Data - Intermediate Resistance and Resistance to Ciprofloxacin among GISP Isolates, 2000-2012
Figure J Data - Distribution of Minimum Inhibitory Concentrations (MICs) to Azithromycin among GISP isolates, 2008-2012
The Gonococcal Isolate Surveillance Project (GISP), a national sentinel surveillance system, was established in 1986 to monitor trends in antimicrobial susceptibilities of Neisseria gonorrhoeae strains in the United States among selected sexually transmitted diseases (STD) clinics in approximately 25-30 GISP sentinel sites.
Annual reports were published for the years 1998–2007. Starting in 2008, site-specific GISP profiles have been published online each year.
The site-specific profiles on the right consist of figures depicting the demographic and clinical data of the men with gonorrhea enrolled in GISP and the antimicrobial susceptibility results of the Neisseria gonorrhoeae isolates submitted.